Hearing Disorders – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000

Empower your strategies with our Hearing Disorders – Drugs In Development, 2024 report and make more profitable business decisions.

Hearing loss is an extremely common medical condition, ranging from neonates to the elderly, progressing in incidence and severity with age; about one-third of older adults have hearing loss. Diagnosis and management require an interprofessional team that includes the general practitioner, otolaryngologist, speech therapist, audiologist, and social worker. To correctly address hearing loss, understanding the nature of hearing loss and the equipment that is needed to improve auditory reception is crucial. In terms of children’s hearing loss, pediatricians need to be integrated into their care to ensure normal hearing and language development of the child. Hearing loss is a common problem caused by loud noise, aging, disease, and genetic variations. The three basic categories of hearing loss are sensorineural hearing loss, conductive hearing loss, and mixed hearing loss. Conductive involves the outer or middle ear, sensorineural involves the inner ear, and mixed involves both. Symptoms of hearing loss may include muffling of speech and other sounds, trouble hearing letters of the alphabet that aren’t vowels, and often asking others to speak more slowly, clearly, and loudly.

The Hearing Disorders drugs in development market research report provide comprehensive information on the therapeutics under development for Hearing Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hearing Disorders and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Hearing Disorders
Key Targets
· Gap Junction Beta 2 Protein; Potassium Voltage Gated Channel Subfamily KQT Member 4 ; Neurotrophic Factor ; Cyclin Dependent Kinase 2; Brain Derived Neurotrophic Factor; Histamine H4 Receptor; Gamma Secretase; Epidermal Growth Factor Receptor ERB1; 5-Hydroxytryptamine Receptor 3; and BDNF/NT 3 Growth Factors Receptor
Key Mechanisms of Action
· Potassium Voltage Gated Channel Subfamily KQT Member 4 Activator; Gap Junction Beta 2 Protein Activator; Cyclin Dependent Kinase 2 Inhibitor; Neurotrophic Factor Activator; NADPH Oxidase 3 Inhibitor; NT 3 Growth Factor Receptor Agonist; Otoferlin Activator; Potassium Voltage Gated Channel Subfamily KQT Member 3 Activator; Potassium Voltage Gated Channel Subfamily C Member 1 Activator; and Potassium Voltage Gated Channel Subfamily KQT Member 2 Activator
Key Routes of Administration
· Oral; Intratympanic; Subcutaneous; Parenteral; Intravenous; Auricular (Otic); Intravenous Bolus; Intravenous Drip; Ophthalmic; and Periarticular
Key Molecule Types
· Small Molecule; Gene Therapy; Cell Therapy; Antisense RNAi Oligonucleotide; Monoclonal Antibody; Biologic; Recombinant Protein; Protein; Peptide; and Fusion Protein
Major Companies
· Regeneron Pharmaceuticals Inc; Ting Therapeutics LLC; Gateway Biotechnology Inc; CILcare SAS; Acousia Therapeutics GmbH; Akouos Inc; Jacaranda Biosciences Inc; IMD Farm Co Ltd; Sound Pharmaceuticals Inc; and Spiral Therapeutics Inc

Scope

  • Therapeutics in Development: Covering 87 molecules, with 81 developed by companies and the rest by universities/institutes.
  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
  • Development History: Access the complete research and development history.
  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Hearing Disorders therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
  • Pipeline Exploration: Explore the detailed Hearing Disorders pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hearing Disorders treatments for adaptable decision-making.
  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

13therapeutics Inc
Acousia Therapeutics GmbH
Adare Pharma Solutions
Affichem SA
Akouos Inc
Anida Pharma Inc
Antion Biosciences SA
Arbormed Co Ltd
AudioCure Pharma GmbH
Audion Therapeutics BV
Autifony Therapeutics Ltd
Bodor Laboratories Inc
Boehringer Ingelheim International GmbH
Calliditas Therapeutics France SAS
Chaperone Therapeutics Inc
CILcare SAS
Daewoong Pharmaceutical Co Ltd
Dendrogenix SA
Gateway Biotechnology Inc
Hoba Therapeutics ApS
HuidaGene Therapeutics Co Ltd
IMD Farm Co Ltd
ImmunityBio Inc
iN Therapeutics Inc
Jacaranda Biosciences Inc
Knopp Biosciences LLC
Kyungpook National University
Lineage Cell Therapeutics Inc
Massachusetts Institute of Technology
Mogrify Ltd
Myrtelle Inc
NeurAegis Inc
Nobelpharma Co Ltd
Novartis AG
O-Ray Pharma Inc
Oblato Inc
Otologic Pharmaceutics Inc
Otonomy Inc
Paean Biotechnology Inc
Pasteur Institute
Perceive Biotherapeutics Inc
Prime Medicine Inc
Quark Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
ReNeuron Group Plc
Rescue Hearing Inc
Rinri Therapeutics Ltd
Rophibio Inc
Sensorion SA
Sinfonia Biotherapeutics Inc
SIU School of Medicine
Sound Pharmaceuticals Inc
Spiral Therapeutics Inc
St. Jude Children’s Research Hospital Inc
Surrozen Inc
Swedish Orphan Biovitrum AB
Ting Therapeutics LLC
Yonsei University
Zebra Biologics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hearing Disorders – Drugs In Development, 2024 in real time.

  • Access a live Hearing Disorders – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.